

COVID-19 VACCINES

ISV VIRTUAL CONGRESS SERIES

2nd Congress July 21, 2020

Registration

www.ISVCongress.org

CONTACT

PHONE:

1-508-856-1179

EMAIL:

Info@ISVCongress.org

<u>Program July 21, 9:00am – 12:00PM (ET)</u>

9:00 am Welcome and Introductions

Chair: Shan Lu, UMass Medical School/ISV Linda Klavinskis, King's College London/ISV Introduction of ISV Virtual Congress

Opening Session (20 min talks + 5 min Q&A)

Chair: Denise Doolan, James Cook University/ISV

9:05am Larry Corey, Fred Hutchinson Cancer Res. Center

COVID Vaccine Planning: The USG Approach

9:30am Marion Gruber, US FDA

Regulatory Considerations in the Development

and Licensure of COVID-19 Vaccines

Scientific Session One (18 min talks + 7 min Q&A)

Part I: Protein and Inactivated Vaccines

Chair: Manon Cox, NextWaveBio/ISV

9:55am Greg Glenn, Novavax

Progress with the Full Length Recombinant Spike

Protein Nanoparticle Vaccine

10:20am George Gao, China CDC

Development of Inactivated COVID-19 Vaccines

Part II: Viral Vector and RNA Vaccines

Chair: Linda Klavinskis, King's College London/ISV

10:45am Hanneke Schuitemaker, J&J/Janssen

The Development of an Ad26-based

SARS-CoV-2 Vaccine

11:10am Kena Swanson, Pfizer

RNA Based COVID-19 Vaccines

Scientific Session Two (25 min panel discussion)

Challenges for COVID-19 Vaccines Development:

The Roles of Animal Models

Moderator: Stanley Perlman, University of Iowa 11:35am Bart Haagmans, Erasmus University

Vincent Munster, RML/NIH

Linda Saif, The Ohio State University

Wrap up and Announcement of 3rd ISV Virtual Congress on COVID-19 Vaccines

12:00PM Shan Lu, ISV

ISV Virtual Congress Series Co-Chairs

Linda Klavinskis, Margaret Liu, Shan Lu / ISV

Senior Advisor

Nick Jackson / CEPI

